Table 10. Country-specific benefit-cost ratios.
| Economic Benefit - Financial Cost1 | Economic Benefit - Economic Cost2 | ||||||
| Country | Year | MDA Round | Avg. Economic Benefit per Person Treated (1-year)3 | Financial Cost per Person Treated4 | Benefit-Cost Ratio (1-year) | Economic Cost per Person Treated4 | Benefit-Cost Ratio (1-year) |
| Burkina Faso * | 2002 | 2 | $1.00 | $0.06 | 16.67 | $4.82 | 0.21 |
| Ghana * | 2002 | 2 | $1.82 | $0.17 | 10.72 | $4.88 | 0.37 |
| Tanzania * | 2003 | 4 | $0.99 | $0.26 | 3.81 | $4.53 | 0.22 |
| Dominican Republic | 2003 | 2 | $4.56 | $0.87 | 5.24 | $1.56 | 2.92 |
| Egypt | 2001 | 2 | $1.64 | $1.00 | 1.64 | $1.34 | 1.23 |
| Haiti (Leogane) | 2002 | 3 | $2.84 | $1.30 | 2.18 | n/a | - |
| Haiti (Milot) | 2002 | 1 | $3.60 | $1.10 | 3.27 | n/a | - |
| Philippines | 2003 | 3 | $3.43 | $0.19 | 18.07 | $0.40 | 8.59 |
Financial cost does not include the cost of ivermectin and albendazole, which are both donated. DEC must be purchased by national programs and is therefore included as a financial cost. Ivermectin is used in combination with albendazole in areas co-endemic for onchocerciasis in Africa plus Yemen. DEC, which is not donated, is used in combination with albendazole in all other countries and must be purchased by national programs.
Economic cost includes the implied cost of donated materials and drugs (Source: Goldman et al. (2007) [54]): US$0.19+$0.0019 for shipping per 400mg tablet of albendazole and US$1.50+$0.0018 per 3mg tablet of ivermectin.
Includes both individual and health system benefits. Currency is adjusted to match year of MDA round.
Source: Goldman et al. (2007) [54].
*Countries receiving the albendazole+ivermectin drug regimen.